286 related articles for article (PubMed ID: 19777735)
1. [Agomelatine].
Tessmer M
Med Monatsschr Pharm; 2009 Aug; 32(8):282-8. PubMed ID: 19777735
[TBL] [Abstract][Full Text] [Related]
2. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
San L; Arranz B
Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
[TBL] [Abstract][Full Text] [Related]
3. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
Kasper S; Hamon M
World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
[TBL] [Abstract][Full Text] [Related]
4. [Agomelatine: the first "melatoninergic" antidepressant].
Bánki MC
Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
[TBL] [Abstract][Full Text] [Related]
5. Agomelatine targets a range of major depressive disorder symptoms.
Dubocovich ML
Curr Opin Investig Drugs; 2006 Jul; 7(7):670-80. PubMed ID: 16869122
[TBL] [Abstract][Full Text] [Related]
6. Agomelatine: a preliminary review of a new antidepressant.
Zupancic M; Guilleminault C
CNS Drugs; 2006; 20(12):981-92. PubMed ID: 17140278
[TBL] [Abstract][Full Text] [Related]
7. Focus on agomelatine.
Green B
Curr Med Res Opin; 2011 Apr; 27(4):745-9. PubMed ID: 21271795
[TBL] [Abstract][Full Text] [Related]
8. Agomelatine for the treatment of major depressive disorder.
Carney RM; Shelton RC
Expert Opin Pharmacother; 2011 Oct; 12(15):2411-9. PubMed ID: 21916789
[TBL] [Abstract][Full Text] [Related]
9. Agomelatine: efficacy at each phase of antidepressant treatment.
Kennedy SH
CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725
[TBL] [Abstract][Full Text] [Related]
10. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.
De Berardis D; Fornaro M; Serroni N; Campanella D; Rapini G; Olivieri L; Srinivasan V; Iasevoli F; Tomasetti C; De Bartolomeis A; Valchera A; Perna G; Mazza M; Di Nicola M; Martinotti G; Di Giannantonio M
Int J Mol Sci; 2015 Jan; 16(1):1111-30. PubMed ID: 25569089
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
Olié JP; Kasper S
Int J Neuropsychopharmacol; 2007 Oct; 10(5):661-73. PubMed ID: 17477888
[TBL] [Abstract][Full Text] [Related]
12. Agomelatine, a melatonin agonist with antidepressant properties.
Dubovsky SL; Warren C
Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
[TBL] [Abstract][Full Text] [Related]
14. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients.
Quera-Salva MA; Hajak G; Philip P; Montplaisir J; Keufer-Le Gall S; Laredo J; Guilleminault C
Int Clin Psychopharmacol; 2011 Sep; 26(5):252-62. PubMed ID: 21829106
[TBL] [Abstract][Full Text] [Related]
15. Agomelatine in treating generalized anxiety disorder.
Demyttenaere K
Expert Opin Investig Drugs; 2014 Jun; 23(6):857-64. PubMed ID: 24766542
[TBL] [Abstract][Full Text] [Related]
16. Treating each and every depressed patient.
Kennedy SH
J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279
[TBL] [Abstract][Full Text] [Related]
17. Agomelatine for major depressive episodes.
Drug Ther Bull; 2010 Aug; 48(8):93-6. PubMed ID: 20685900
[TBL] [Abstract][Full Text] [Related]
18. Agomelatine as chronopsychopharmaceutics restoring circadian rhythms and enhancing resilience to stress: a wishfull thinking or an innovative strategy for superior management of depression?
Jakovljević M
Psychiatr Danub; 2011 Mar; 23(1):2-9. PubMed ID: 21448091
[TBL] [Abstract][Full Text] [Related]
19. Major depressive disorder, sleep EEG and agomelatine: an open-label study.
Quera Salva MA; Vanier B; Laredo J; Hartley S; Chapotot F; Moulin C; Lofaso F; Guilleminault C
Int J Neuropsychopharmacol; 2007 Oct; 10(5):691-6. PubMed ID: 17477886
[TBL] [Abstract][Full Text] [Related]
20. Agomelatine: innovative pharmacological approach in depression.
Popoli M
CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
